Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MISTIE: Minimally Invasive Surgery and rtPA for ICH
NCT00224770Phase 2Completed
- Start
- Aug 2005
- Primary completion
- Aug 2012
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in intracerebral hemorrhage (ICH) (3 arms). Primary endpoints: Rate of Mortality at 30 days, Rate of Procedure-related Mortality at 7 days and 3 more. Started Aug 2005; status: completed.
02
Drugs
tissue-plasminogen activator
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT00224770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224770.